01—Abstract
Summary
Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported second quarter 2024 revenue of $1,004 milliona, up 6% as reported and 7% organic, led by Companion Animal Group (CAG) growth of 6% reported and 7% organic.
CAG Diagnostics recurring revenue grew 6%b reported and 7% organic, with international regions up 8% reported and 10% organic and U.S. up 5%. Operating indicators were solid: record second quarter premium instrument placements, 11% growth in the global premium installed base, and gross margin of 61.7% (up 100 bps as reported). Water revenue rose 9% reported and 10% organic, while LPD grew 1% reported and 3% organic.
The headline issue is a $61.5 millionc discrete expense accrual (about $0.56 per share) for an ongoing litigation matter involving alleged underpayment of royalties from 2004 through 2017 under an expired patent license. This pushed reported Q2 diluted EPS down 9% to $2.44 and operating margin down 510 bps to 26.3%. Excluding the charge, comparable EPS rose 15% to $3.02 and comparable operating margin expanded 110 bps to 32.4%.
The company's total accrual for the matter is now $89.0 milliond, and the actual loss could be higher or lower. Management lowered its 2024 revenue guidance to $3,885-$3,945 million (6.2%-7.8% growth, organic and reported) from $3,895-$3,965 million, citing recent U.S. clinical visit trends.
The reported EPS outlook was cut to $10.31-$10.59 from $10.82-$11.20, a $0.56 midpoint reduction driven entirely by the litigation accrual, while comparable EPS growth guidance of 9%-12% was maintained. Investors will likely focus on the sustainability of U.S. clinical visit trends and on the Investor Day scheduled for August 15, 2024.
02—Key points
Key Highlights
- Q2 2024 revenue of $1,004 million grew 6% as reported and 7% organic, with CAG up 6% reported and 7% organic.
- CAG Diagnostics recurring revenue grew 6% reported and 7% organic; international grew 8% reported and 10% organic, while U.S. grew 5%.
- Record Q2 premium instrument placements and 11% year-over-year growth in the global premium instrument installed base.
- Reported diluted EPS fell 9% to $2.44 due to a $61.5M ($0.56/share) litigation accrual; comparable EPS rose 15% to $3.02.
- Reported operating margin of 26.3% was down 510 bps, including roughly 610 bps of impact from the litigation charge; comparable operating margin rose 110 bps to 32.4%.
- 2024 revenue guidance was narrowed to $3,885-$3,945 million from $3,895-$3,965 million, reflecting softer U.S. clinical visit trends (about 1% lower organic growth at midpoint).
- 2024 reported EPS outlook was cut to $10.31-$10.59 from $10.82-$11.20, while comparable EPS growth of 9%-12% was maintained; Investor Day is set for August 15, 2024.
03—Questions
Frequently Asked Questions
What caused the drop in reported EPS and operating margin in Q2 2024?
A $61.5 million discrete expense accrual, which increased a previously established $27.5 million accrual for an ongoing litigation matter, brought the total accrual to $89.0 million. The charge reduced Q2 diluted EPS by $0.56 and cut operating margin by roughly 610 bps. Excluding it, comparable EPS grew 15% and comparable operating margin expanded 110 bps.
What is the litigation matter, and could the cost rise further?
IDEXX is a defendant in a breach-of-contract suit alleging underpayment of royalties from 2004 through 2017 under an expired patent license agreement. The company says $89.0 million represents its best estimate of probable loss, but the actual loss may be higher or lower depending on the outcome. Further details are in the Q2 2024 Form 10-Q.
Did IDEXX change its full-year 2024 outlook?
Yes. Revenue guidance was narrowed to $3,885-$3,945 million (6.2%-7.8% growth) from $3,895-$3,965 million, with organic growth reduced about 1% at midpoint due to recent U.S. clinical visit trends. Reported EPS guidance fell to $10.31-$10.59 from $10.82-$11.20, reflecting the $0.56 litigation charge. Comparable EPS growth of 9%-12% was kept, and reported operating margin guidance is 28.7%-29.0%.
How healthy is the underlying business apart from the one-time charge?
The core business remained solid. Revenue grew 7% organically, gross margin expanded 100 bps to 61.7%, and free cash flow for the first half was $383 million, up from $317 million. CAG Diagnostics recurring revenue grew 7% organically, and the premium installed base grew 11%, which supports future consumables revenue. The main caution is softer U.S. clinical visit levels, which prompted the revenue guidance reduction.
What should investors watch next?
Investors should monitor U.S. clinical visit trends, the trajectory of premium instrument placements and installed base growth, and any updates to the litigation accrual. The 2024 Investor Day on August 15, 2024, will provide more detail on long-term strategy and financial targets.
04—Continue